By Focusing on a novel theranostic target we develop innovative biomedicines for intractable inflammatory immune disorders
that cannot be cured with existing therapies.

Our Ground-breaking Discovery

For the first time, we found that secreted human Tryptophanyl- tRNA synthetase (WARS1) is an endogenous ligand for TLR2 and TLR4, making it a potent inducer of innate inflammatory responses.

We further discovered that WARS1 is a "theranostic (diagnosis and therapy) target" for life-threatening inflammatory diseases because not only does it identify patients who can benefit from WARS1 therapy, but it also serves as a therapeutic target based on the biological mechanism.


Our Mission

Save lives by performing 'WITheranostics' excellence !